TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03404375

Intervention type: DEVICE
Group type: OTHER
Intervention: Gauss Triton system
Description: The Triton system (Gauss Surgical, Inc., Palo Alto, CA) is a novel mobile monitoring platform that combines mobile computing with Gauss Feature Extraction Technology (FET) to directly assess Hb mass (mHb) absorbed by surgical sponges from an image. The device is an iPad like imaging device that will assess blood loss via imaging of the surgical sponges used in the surgery.~The device will be used to calculate blood loss on every patient enrolled in the study.
Study: NCT04239664

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acceptance Based Telephone Support (ABS+UC)
Description: Support based on Acceptance and Committment Therapy (Hayes, 1999)
Study: NCT02903108

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SRP plus boric acid gel
Description: SRP followed by 0.75% boric acid placement into intrabony defect

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SRP plus placebo gel
Description: SRP followed by placebo gel placement into intrabony defect
Study: NCT01136590

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: A 10-mg/kg dose of tranexamic acid will be administered as a bolus or as a fast, 20-minute intravenous infusion before performing the incision at the start of surgery, followed by perfusion of 2 mg/kg/hour up to the time the surgical wound is closed at completion of surgery.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: fisiologic serum
Description: The placebo will be administered according to the same regimen and infusion time as the medication in the study arm (bolus or 20-minute fast infusion before the incision at the beginning of surgery followed by perfusion of 2 mg/kg/hour until closure of the surgical wound at completion of surgery)
Study: NCT02820389

Intervention type: PROCEDURE
Intervention: Optical colonoscopy
Description: Patients with suspected colorectal cancer in this group will undergo Optical Colonoscopy as the initial imaging modality.

Intervention type: PROCEDURE
Intervention: CTC
Description: Patients with suspected colorectal cancer in this group will undergo Computed Tomography Colonography (CTC) as the initial imaging modality. Subsequent imaging might be required based on the findings from the CTC scan, i.e. patients with medium to large polyps or colorectal cancer will undergo Optical Colonoscopy as the second imaging test.
Study: NCT01866371

Intervention type: PROCEDURE
Intervention: Retinal imaging
Description: Retinal imaging procedures include adaptive optics imaging, optical coherence tomography and fundus photography.

Intervention type: PROCEDURE
Intervention: Retinal imaging
Description: Retinal imaging procedures include adaptive optics imaging, optical coherence tomography and fundus photography.
Study: NCT00714480

Intervention type: DRUG
Group type: OTHER
Intervention: anti-thymocyte globulin
Description: Administration of anti-thymocyte globulin at post-operative days -6, -4, -2 and 0
Study: NCT01838057

Intervention type: OTHER
Intervention: Control cohort
Description: A matched group of low back pain patients not managed with painPREMIER.
Study: NCT00714480

Intervention type: DRUG
Group type: OTHER
Intervention: anti-thymocyte globulin
Description: anti-thymocyte globulin post-operative days -2, 0, 2 and 4
Study: NCT01867489

Intervention type: OTHER
Intervention: No intervention
Study: NCT03448744

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymosin Alpha1
Description: Thymosin Alpha1 (1.6 mg subcutaneously injection twice a week) plus ETV (0.5 mg orally, daily) for 24 weeks, and followed by continuous ETV for at least 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir
Description: ETV (0.5 mg orally, daily) for 72 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Entecavir
Description: ETV (0.5 mg orally, daily) for 72 weeks
Study: NCT02752828

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glargine/lixisenatide (HOE901/AVE0010)
Description: Pharmaceutical form: solution~Route of administration: subcutaneous
Study: NCT00714480

Intervention type: DRUG
Group type: OTHER
Intervention: anti-thymocyte globulin
Description: Post-operative days 0, 2, 4 and 6
Study: NCT00498550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clozapine
Description: Clozapine up to 550mg per day
Study: NCT02199327

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mitomycin C
Description: Patients treated with mitomycin will be handled by cycles until resolution of the lesion, which according to previous studies is expected between 3 and 6 cycles (between half months and 3 months).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Interferon Alfa-2b
Description: Patients managed with interferon will be treated for a period ranging from one month to 12 months according to clinical resolution of the lesion. Both groups will be evaluated by at least one year after the resolution of the lesion to determine the presence of recurrences
Study: NCT02126748

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: inhalation 4ml hypertonic saline 3% 3x/day

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: inhalation 4ml hypertonic saline 3% 3x/day

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intrapulmonary Percussive Ventilation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Assisted Autogenic Drainage
Study: NCT04309123

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TransAeris System
Description: The TransAeris System is a temporary percutaneous intramuscular diaphragm stimulator intended for patients at risk of or on prolonged positive pressure mechanical ventilation. TransAeris is indicated for use in the prevention and treatment of ventilator-induced diaphragm dysfunction (VIDD).
Study: NCT01470443

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin 130mg/㎡, day 1, every 3 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Oxaliplatin 100 mg/㎡, day 1, every 3 weeks
Study: NCT04787081

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sleep Care Positioning Training Program GRP1
Description: Video-based tutorial covering six nighttime postural care topic areas which contained narration and closed captioning. This 2-hour online training program was delivered in a University classroom via D2L Brightspace.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sleep Care Positioning Training Program GRP2
Description: Web-link based tutorial covering six nighttime postural care topic areas which contained mostly written content. This self-paced online training program was delivered in a University classroom via D2L Brightspace.
Study: NCT02034344

Intervention type: PROCEDURE
Intervention: Skin biopsy
Description: Participants with LE will have 2 adjacent 4 mm punch biopsies collected from involved and uninvolved skin at one timepoint and again from the involved skin site approximately 12 weeks later. Healthy participants will have 2 adjacent 4 mm punch biopsies taken at one timepoint.

Intervention type: PROCEDURE
Intervention: Skin biopsy
Description: Participants with LE will have 2 adjacent 4 mm punch biopsies collected from involved and uninvolved skin at one timepoint and again from the involved skin site approximately 12 weeks later. Healthy participants will have 2 adjacent 4 mm punch biopsies taken at one timepoint.

Intervention type: PROCEDURE
Intervention: Skin biopsy
Description: Participants with LE will have 2 adjacent 4 mm punch biopsies collected from involved and uninvolved skin at one timepoint and again from the involved skin site approximately 12 weeks later. Healthy participants will have 2 adjacent 4 mm punch biopsies taken at one timepoint.

Intervention type: PROCEDURE
Intervention: Blood collection
Description: Blood for serum analyses will be taken from all participants. Blood for DNA analysis will only be taken from participants who consent to this separately.
Study: NCT00498550

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Remain on pre-study antipsychotic treatment
Study: NCT02918344

Intervention type: OTHER
Intervention: Hydroset
Description: Calcium phosphate paste is used in mandibular lengthening surgery to avoid an unaesthetic notching at the lower border and to help stabilize the segments when osteosynthesis slippage is feared for.

Intervention type: OTHER
Intervention: Hydroset
Description: Calcium phosphate paste is used in mandibular lengthening surgery to avoid an unaesthetic notching at the lower border and to help stabilize the segments when osteosynthesis slippage is feared for.
Study: NCT02752828

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin glargine (HOE901)
Description: Pharmaceutical form: solution~Route of administration: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral anti-diabetic drugs
Description: Pharmaceutical form: tablet~Route of administration: oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral anti-diabetic drugs
Description: Pharmaceutical form: tablet~Route of administration: oral
Study: NCT02016014

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smartphone with APP
Description: Smartphone with APP (EVIDENT) for 3 months
Study: NCT02918344

Intervention type: PROCEDURE
Intervention: Standard sagittal split osteotomy
Description: The sagittal split osteotomy (SSO) is commonly used to correct dentofacial discrepancies.

Intervention type: PROCEDURE
Intervention: Standard sagittal split osteotomy
Description: The sagittal split osteotomy (SSO) is commonly used to correct dentofacial discrepancies.
Study: NCT03638466

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Functional Magnetic Resonance Imaging (fMRI)
Description: Neural brain activity measured by fMRI

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Functional Magnetic Resonance Imaging (fMRI)
Description: Neural brain activity measured by fMRI

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Magnetic Resonance Spectroscopy (MRS)
Description: Glutamate and GABA levels measured by MRS

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Spectroscopy (MRS)
Description: Glutamate and GABA levels measured by MRS
Study: NCT02016014

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counseling on lifestyles
Description: Counseling on physical activity and mediterranean diet

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Counseling on lifestyles
Description: Counseling on physical activity and mediterranean diet
Study: NCT02529527

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MyFamilyPlan
Description: Web-based preconception health education tool (interactive self-assessment) - to be completed by patient
Study: NCT03638466

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Point Subtraction Aggression Paradigm (PSAP) Task
Description: Aggression score measured by the PSAP task

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Point Subtraction Aggression Paradigm (PSAP) Task
Description: Aggression score measured by the PSAP task

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SPN-810
Description: Treatment of SPN-810 36 mg on neuronal brain activity, GABA and Glutamate levels and on the aggression score

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Treatment of placebo on neuronal brain activity, GABA and Glutamate levels and on the aggression score
Study: NCT02034344

Intervention type: PROCEDURE
Intervention: Blood collection
Description: Blood for serum analyses will be taken from all participants. Blood for DNA analysis will only be taken from participants who consent to this separately.
Study: NCT01769911

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carmustine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: O6-benzylguanine
Description: Given IV
Study: NCT03410290

Intervention type: OTHER
Intervention: Online Questionnaire
Description: The online questionnaire includes questions about factors that impacted a patients diagnosis of vasculitis.
Study: NCT01842087

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control Food
Description: For a period of 2 weeks, participants will consume control foods in addition to their usual diets.
Study: NCT01769911

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous hematopoietic stem cell transplantation
Description: Undergo transduced and/or non-transduced transplant

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: Undergo transduced and/or non-transduced transplant

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT03542838

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Resiniferatoxin
Description: Resiniferatoxin is a compound purified from natural sources.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline is a normal physiological solution
Study: NCT01455350

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multimodal physiotherapy
Description: 10 weeks of weekly physiotherapy treatments including relaxation techniques, stretching and pelvic floor muscle control exercises.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine
Description: 10 weeks of daily topical 5% lidocaine application
Study: NCT02034344

Intervention type: PROCEDURE
Intervention: Urine collection
Description: Urine will be collected from all participants.

Intervention type: PROCEDURE
Intervention: Urine collection
Description: Urine will be collected from all participants.

Intervention type: PROCEDURE
Intervention: Urine collection
Description: Urine will be collected from all participants.
Study: NCT04279197

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fuzheng Huayu Tablet
Description: FZHY, administration: 0.4g/tablet, 1.6g/time, 3 times/day, oral; administered half an hour after the meal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin C tablets
Description: Vitamin C tablets, administration: 0.2g/time, 3 times/ day, oral；
Study: NCT00868517

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: True group auricular acupuncture
Description: Received true group auricular acupuncture
Study: NCT04279197

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin C tablets
Description: Vitamin C tablets, administration: 0.2g/time, 3 times/ day, oral；

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo , administration: 0.4g/tablet, 1.6g/time, 3 times/day, oral; administered half an hour after the meal.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: respiratory function rehabilitation training
Description: Health exercise, once a day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: respiratory function rehabilitation training
Description: Health exercise, once a day
Study: NCT03191968

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supervised Physical Activity Plus Behavioral Counseling
Description: In addition to supervised physical activity, behavioral counseling sessions will be delivered with a PA specialist based on the Multi-process Action Control (M-PAC) framework and include behavior change techniques addressing information regarding the consequences, social support, goal setting, self-monitoring, cues and prompts, barrier identification, intention formation, planning, and habit and identity formation

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supervised Physical Activity Plus Exercise Counseling
Description: In addition to the supervised exercise sessions, standard exercise counseling will be delivered by a PA specialist to teach proper PA and resistance training techniques, how to monitor intensity, and to progress PA safely and effectively to achieve the public health PA guideline.
Study: NCT01842087

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fiber Fortified Food
Description: For a period of 4 weeks, participants will consume food fortified with fiber in addition to their usual diets.
Study: NCT05892198

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgery
Description: surgery with primary closure, Rhomboid flap , or Rotational flap

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgery
Description: surgery with primary closure, Rhomboid flap , or Rotational flap

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgery
Description: surgery with primary closure, Rhomboid flap , or Rotational flap
Study: NCT01092923

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sevoflurane on air/O2
Description: sevoflurane on air/O2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sevoflurane in N2O/O2
Description: sevoflurane in N2O/O2
Study: NCT01518530

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Occiflex Robotic Intervention System
Description: Occiflex is a robotic system which is comprised of a cradle moved in a three dimension space with six degrees of freedom. It allows the therapist to tailor a personalized course of 3-D mobilization of the head and neck.
Study: NCT00524498

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC-18
Description: OPC-18: 500IU \* 3 times a week, sc 5-FU : 500mg infusion for 5days into hepatic artery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin
Description: infusion into hepatic artery with cisplatin 10mg and 5-FU 250mg a day
Study: NCT00868517

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham group auricular acupuncture
Description: Received sham auricular acupuncture.

Intervention type: OTHER
Group type: OTHER
Intervention: Wait-List Control Group
Description: Received conventional care only. Eligible to receive true group auricular acupuncture once study period completed.
Study: NCT03180736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Daratumumab will be given at a dose of 16 mg/kg administered as an IV infusion (Dara IV) or 1800 mg subcutaneously (Dara SC) at weekly intervals (QW) for 8 weeks, then every 2 weeks (Q2W) for an additional 16 weeks, then every 4 weeks (Q4W) thereafter. Subjects will receive pre-infusion medications before infusions to mitigate potential IRRs.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Pomalidomide will be administered at full dose of 4 mg orally (PO) on Days 1 through 21 of each 28-day cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pomalidomide
Description: Pomalidomide will be administered at full dose of 4 mg orally (PO) on Days 1 through 21 of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone will be administered at a dose of 40 mg (20 mg for patients ≥75 years of age) orally, once daily on Days 1, 8, 15, and 22 of each 28-day treatment cycle.
Study: NCT03618277

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Biopsy
Description: Micro-biopsies will be performed using a punch of 1 mm in diameter, by pulling the skin at the time of sampling, after disinfection and anesthesia.
Study: NCT02124174

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vidaza and Valproic Acid
Description: Days 1-5: 5-Azacytidine 40 mg/m\^2 daily Days 1-5: +Valproic acid 15 mg/kg daily Days 6-28: Valproic acid 15 mg/kg daily~\*treatments will be repeated on the same days of each cycle for up to 4 total cycles. Each cycle will consist of 28 days.
Study: NCT03606824

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pitavastatin and placebo
Description: The initial dosage of pitavastatin is 2mg, and it will be regulated according to the level of LDL-C and the upper limit is 4mg.Since the investigators are blind to the arms,the fake regulation of placebo dosage will be same as the Pitavastatin and levothyroxine group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pitavastatin and levothyroxine
Description: The initial dosage of pitavastatin is 2mg and the initial dosage of levothyroxine is 12.5ug. The dosage of levothyroxine will be regulated according to thyroid function test every 2-3 weeks. The regulation of pitavastatin dosage is same as the monotherapy group.
Study: NCT01614418

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endoscopic radiofrequency ablation catheter
Description: Endoscopic radiofrequency ablation
Study: NCT02795143

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isotretinoin

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00274456

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABI-007
Description: ABI-007 administered by intravenous infusion over 30 minutes at one of three different dosing levels (100, 150 or 300 mg/m\^2) with a treatment cycle length of either 3 or 4 weeks depending upon treatment arm assignment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABI-007
Description: ABI-007 administered by intravenous infusion over 30 minutes at one of three different dosing levels (100, 150 or 300 mg/m\^2) with a treatment cycle length of either 3 or 4 weeks depending upon treatment arm assignment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABI-007
Description: ABI-007 administered by intravenous infusion over 30 minutes at one of three different dosing levels (100, 150 or 300 mg/m\^2) with a treatment cycle length of either 3 or 4 weeks depending upon treatment arm assignment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel dosed q3w at 100 mg/m\^2
Study: NCT01730196

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fit Body and Soul

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Wellness Education
Study: NCT03180736

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone will be administered at a dose of 40 mg (20 mg for patients ≥75 years of age) orally, once daily on Days 1, 8, 15, and 22 of each 28-day treatment cycle.
Study: NCT00049127

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib Mesylate
Description: Given PO
Study: NCT03207438

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine 50 MG Extended Release Oral Tablet
Description: OD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine Fumarate XR 150-300 mg
Description: Dose ranged from 150 to 300mg, XR preparation, OD

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo